News
ImmuneBridge’s expansion technology expands hematopoietic stem cells (HSCs), which are natural precursors of NK cells. HSCs are readily available via umbilical cord blood from public cord blood ...
Large granular lymphocytic leukemias (LGLLs), including T-cell LGLL and natural kill (NK)-cell LGLL variants, are rare lymphoproliferative disorders characterized by the chronic proliferation of ...
HebeCell Corp, founded in 2016, is primarily engaged in developing universal and cost-effective NK cell therapeutics based on its proprietary 3D pluripotent stem cell (PSC) platform, the off-the ...
NK:IO, a leader in NK cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, today announced it has been awarded £1.6M in grant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results